Results 71 to 80 of about 919 (164)

Effect of Ocriplasmin on the Management of Macular Holes [PDF]

JAMA Ophthalmology, 2014
Assessing the effect of ocriplasmin availability on the management of full-thickness macular holes (MHs) is important for vitreoretinal surgeons and their patients. Such an assessment can indicate whether the use of ocriplasmin will bring a paradigm shift in treating MHs or will be just an additional option relevant to a small group of patients.To ...
Joseph, Moisseiev, Iris, Moroz, Gabriel, Katz   +2 more
openaire   +2 more sources

[Cost-effectiveness analysis of ocriplasmin in the treatment of vitreomacular traction in Italy] [PDF]

, 2015
BACKGROUND: Vitreomacular traction (VMT) caused by vitreomacular adhesion (VMA), is a pathological condition when the vitreous humor has an abnormally strong attachment to the central part of the retina. Ocriplasmin recently approved for the treatment of
Miglietta, Riccardo, Rizzo, Stanislao, D\u27Angiolella, Lucia Sara, Bandello, Francesco, Mantovani, Lorenzo Giovanni   +4 more
core   +1 more source

Profile of ocriplasmin and its potential in the treatment of vitreomacular adhesion

Clinical Ophthalmology, 2014
Francisco R Stefanini,1–3 Maurício Maia,1 Paulo Falabella,1–3 Marcel Pfister,2,3 Moritz Niemeyer,2 Amir H Kashani,3 Mark S Humayun,3 Michael J Koss2,3,41Retina Division, Department of Ophthalmology and Visual Sciences, Federal ...
Stefanini FR, Maia M, Falabella P, Pfister M, Niemeyer M, Kashani AH, Humayun MS, Koss MJ   +7 more
doaj  

Comparison of Guided and Unguided Ocriplasmin Injection for the Treatment of Vitreomacular Traction: A Preliminary Study

Journal of Ophthalmology, 2016
This retrospective quality control study aimed at comparing resolution in patients treated with intravitreal ocriplasmin (IVO) using two injection techniques, classical injection procedure (unguided) and targeted injection using a surgical microscope ...
Rodolfo Mastropasqua, Luca Di Antonio, Vincenzo Ciciarelli, Agbeanda Aharrh-Gnama, Marco Rispoli, Paolo Carpineto   +5 more
doaj   +1 more source

Early Evolution of the Vitreomacular Interface and Clinical Efficacy After Ocriplasmin Injection for Symptomatic Vitreomacular Adhesion

, 2015
BACKGROUND AND OBJECTIVE: To determine early evolution of the vitreomacular interface and clinical efficacy and safety profile after ocriplasmin treatment. PATIENTS AND METHODS: Retrospective, multicenter, observational case series.
Shah, Gaurav K., Stalmans, Peter, Blinder, Kevin J., Reichel, Elias, Tewari, Asheesh, Meyer, Jacob C., Singer, Michael, Waheed, Nadia K., Nadia K. Waheed, Peter Stalmans, Elias Reichel, Jacob C. Meyer, Asheesh Tewari, Michael Singer, Gaurav K. Shah, Kevin J. Blinder   +15 more
core   +1 more source

Intravitreal ocriplasmin treatment in stage 2 macular hole due to vitreomacular traction VitreomakÜler traksiyona baǧli evre 2 tam kat akÜla deliǧinde intravitreal okriplazmin tedavisi

, 2013
We report the closure of a stage 2 macular hole with the release of vitreomacular traction in an eye with traction related stage 2 macular hole following the injection of 0.125 mg ocriplasmin.
Eldem, Bora, SAATCİ, ALİ OSMAN, ÖZBEK, ZEYNEP, YAMAN, AYLİN, KADAYIFÇILAR, SİBEL   +4 more
core   +1 more source

Ocriplasmin for symptomatic vitreomacular adhesion: an evidence-based review of its potential [PDF]

, 2014
Vitreomacular traction is a multicategory entity that may cause substantial visual loss due to the formation of a macular hole or traction-induced tissue distortion.
Smiddy, William E, Song, Su Jeong
core   +1 more source

Autolytic degradation of ocriplasmin: a complex mechanism unraveled by mutational analysis

, 2014
Ocriplasmin, a truncated form of plasmin, is commercialized in the USA and in Europe under the trade name Jetrea(®), and indicated for the treatment of symptomatic vitreomacular adhesion and vitreomacular traction including when associated with macular ...
Aerts, F., Fonteyn, L., Vanhove, M., Barbeaux, P., De Maeyer, Marc, De Vriese, A., Noppen, B., Zwaal, R., Le Floch, F.   +8 more
core   +1 more source

Treatment of vitreomacular traction with intravitreal ocriplasmin preceded by anterior chamber paracentesis: Case reports

, 2016
Purpose: To evaluate the efficacy of an intravitreal ocriplasmin injection using anterior chamber paracentesis to release symptomatic vitreomacular traction (VMT).Methods: Five patients with symptomatic VMT were enrolled.All patients underwent a complete
Bacherini D., Rizzo S., Virgili G.
core   +1 more source

Effect of Funding Source on “Spin” in Studies of Ocriplasmin Therapy for Vitreomacular Traction and Macular Hole

Clinical Ophthalmology, 2020
Sasha Hubschman, 1 Michael J Venincasa, 1 Ajay E Kuriyan, 2 Jayanth Sridhar 1 1Department of Ophthalmology, Bascom Palmer Eye Institute, Miller School of Medicine, University of Miami, Miami, FL, USA; 2Department of Ophthalmology, Flaum Eye Institute ...
Hubschman S, Venincasa MJ, Kuriyan AE, Sridhar J   +3 more
doaj